Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES.

Abstract : IRESs (internal ribosome entry sites) are RNA elements behaving as translational enhancers in conditions of global translation blockade. IRESs are also useful in biotechnological applications as they allow expression of several genes from a single mRNA. Up to now, most IRES-containing vectors use the IRES from encephalomyocarditis virus (EMCV), highly active in transiently transfected cells but long and not flexible in its positioning relative to the gene of interest. In contrast, several IRESs identified in cellular mRNAs are short and flexible and may therefore be advantageous in gene transfer vectors such as those derived from the adeno-associated virus (AAV), where the size of the transgene expression cassette is limited. Here, we have tested bicistronic AAV-derived vectors expressing two luciferase genes separated by the EMCV- or fibroblast growth factor 1 (FGF-1) IRES. We demonstrate that the AAV vector with the FGF-1 IRES, when administrated into the mouse muscle, leads to efficient expression of both transgenes with a stable stoechiometry, for at least 120 days. Interestingly, the bicistronic mRNA containing the FGF-1 IRES leads to transgene expression 10 times superior to that observed with EMCV, in vivo. AAV vectors featuring the FGF-1 IRES may thus be advantageous for gene therapy approaches in skeletal muscle involving coexpression of genes of interest.
Type de document :
Article dans une revue
Gene Ther, 2008, 15 (15), pp.1090-8. 〈10.1038/gt.2008.49〉
Liste complète des métadonnées

Contributeur : Marie Francoise Simon <>
Soumis le : lundi 28 septembre 2009 - 15:13:09
Dernière modification le : jeudi 13 septembre 2018 - 10:26:05

Lien texte intégral




Aurélie Delluc-Clavières, Christine Le Bec, Loïc Van den Berghe, Caroline Conte, Valérie Allo, et al.. Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES.. Gene Ther, 2008, 15 (15), pp.1090-8. 〈10.1038/gt.2008.49〉. 〈inserm-00420254〉



Consultations de la notice